Is BIO.DE stock a buy right now?

We view BIO.DE stock as a short-term bounce trade, not a long-term buy. Meyka AI gives a **B** grade and suggests HOLD. Watch for volume above **200** shares and price action above **€42.80** before scaling in.

What are the main risks for BIO.DE stock?

Major risks include negative EPS (**-0.63**), tight free cash flow, and higher leverage with debt-to-equity **1.31**. Sector shocks in biotech or weak earnings can push shares below **€40.40**.

What price targets should traders use for BIO.DE stock?

A tactical target for an oversold bounce is **€44.00**. Meyka AI's one-year model projects **€42.05**, implying small downside. Use stops near **€40.80** for defined risk.

How does company data affect the BIO.DE stock outlook?

Biotest’s liquidity ratios and current ratio **4.93** support near-term stability, but negative margins and cash-flow metrics weigh on the outlook. Monitor earnings and inventory days at **500.13** for operational risk signals.

DE Stocks

BIO.DE Biotest AG on XETRA pre-market: €42.20 shows oversold bounce opportunity

ByHuzaifa Zahoor January 24, 2026January 24, 2026

BIO.DE stock trades at €42.20 in XETRA pre-market and looks set for an oversold bounce setup after a modest pullback. We see low volume of 175 shares early today and a year range of €40.40–€43.20, which frames a tight trading band. As an AI-powered market analysis platform, Meyka AI flags this as a short-term mean-reversion trade for traders watching liquidity and catalysts in Germany’s biotechnology sector.